Zacks: Analysts Expect OvaScience Inc (OVAS) Will Post Quarterly Sales of $100,000.00
Wall Street analysts expect OvaScience Inc (NASDAQ:OVAS) to report sales of $100,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for OvaScience’s earnings, with the highest sales estimate coming in at $100,000.00 and the lowest estimate coming in at $90,000.00. OvaScience posted sales of $120,000.00 in the same quarter last year, which would indicate a negative year over year growth rate of 16.7%. The firm is expected to announce its next quarterly earnings report on Thursday, March 1st.
According to Zacks, analysts expect that OvaScience will report full-year sales of $100,000.00 for the current fiscal year, with estimates ranging from $290,000.00 to $300,000.00. For the next year, analysts expect that the business will post sales of $2.91 million per share, with estimates ranging from $300,000.00 to $5.52 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow OvaScience.
A number of brokerages have recently issued reports on OVAS. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of OvaScience in a report on Monday, November 6th. Zacks Investment Research cut OvaScience from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP bought a new stake in OvaScience during the 4th quarter worth approximately $342,000. Deutsche Bank AG grew its position in OvaScience by 7,476.4% during the 4th quarter. Deutsche Bank AG now owns 517,693 shares of the biotechnology company’s stock worth $724,000 after acquiring an additional 510,860 shares during the last quarter. Renaissance Technologies LLC grew its position in OvaScience by 6,531.3% during the 4th quarter. Renaissance Technologies LLC now owns 782,165 shares of the biotechnology company’s stock worth $1,095,000 after acquiring an additional 770,370 shares during the last quarter. GMT Capital Corp bought a new stake in OvaScience during the 3rd quarter worth approximately $1,138,000. Finally, Wells Fargo & Company MN grew its position in OvaScience by 28.8% during the 2nd quarter. Wells Fargo & Company MN now owns 164,283 shares of the biotechnology company’s stock worth $256,000 after acquiring an additional 36,720 shares during the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.
OvaScience Company Profile
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.